Faeth Therapeutics, Inc（FTH）資訊與事件FTHFaeth Therapeutics, Inc

Faeth Therapeutics Grants 94,000 Stock Options to New Employees

Faeth Therapeutics announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company's common stock in connection with their employment. The Option Awards were granted effective August 25, 2026, pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance with Nasdaq Listing Rule 5635(c)(4).

Faeth Therapeutics Completes Merger with Sensei Biotherapeutics, Secures $200 Million Financing

"Our combination with Sensei Biotherapeutics marked an important milestone in the history of Faeth Therapeutics," said Anand Parikh, Chief Executive Officer. "With the concurrent $200 million PIPE financing, we now have the capital to interrogate the multi-nodal hypothesis in multiple cancers. We look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer, which is expected by year-end."

Faeth Therapeutics Trading Halted Due to Volatility

Faeth Therapeutics, Inc trading halted, volatility trading pause